New members bring deep immunology drug development expertise and financial leadership as Talawar advances TALA-125 toward the clinic

WALTHAM, Mass., Oct. 1, 2026 /PRNewswire/ — Talawar Therapeutics (“Talawar” or the “Company”), a biotechnology company developing potentially best-in-class bispecific antibodies for immunology and inflammatory (I&I) diseases, today announced the appointment of Mittie Doyle, MD, and Susannah Gray to its Board of Directors.

“We are thrilled to welcome Mittie and Susannah to Talawar’s Board of Directors,” said Marc Schegerin, MD, MBA, Chief Executive Officer of Talawar. “Mittie’s deep clinical development experience across immunology, rheumatology and dermatology will be a valuable resource as we advance TALA-125 toward the clinic, and Susannah’s extensive financial and capital markets expertise will be instrumental as we build the governance and financial discipline of a public company. Their combined perspectives arrive at a pivotal moment for Talawar, and we look forward to their contributions.”

Dr. Doyle brings more than 20 years of clinical development experience in the pharmaceutical and biotechnology industry, with expertise in immunology, rheumatology and dermatology. She currently serves as Chief Medical Officer of Avalo Therapeutics, a clinical stage biotechnology company developing therapeutics for immune-mediated inflammatory diseases. She previously served as Chief Medical Officer of Aro Biotherapeutics and held senior leadership roles at CSL Behring, Shire Pharmaceuticals, Flexion Therapeutics and Alexion Pharmaceuticals. Dr. Doyle has led teams responsible for the design and execution of first-in-human through late-stage clinical trials across a broad range of immune-mediated and orphan diseases, resulting in multiple global regulatory approvals. She currently serves on the boards of Cullinan Therapeutics and Santa Ana Bio, and previously served on the board of DICE Therapeutics until its acquisition by Eli Lilly and Company. Dr. Doyle received her BA, magna cum laude, from Princeton University and her MD, cum laude, from Yale Medical School, and completed her postdoctoral training at Harvard Medical School, including a residency in Internal Medicine at Massachusetts General Hospital and a fellowship in Rheumatology and Immunology at Brigham and Women’s Hospital.

“I am excited to join Talawar’s Board at such a promising moment for the Company,” said Dr. Doyle. “TALA-125’s dual mechanism represents a compelling approach designed to unlock durable impact for patients living with immune and inflammatory diseases, and I look forward to supporting the team as they advance the program into the clinic.”

Ms. Gray brings more than 30 years of biopharmaceutical corporate finance and capital markets experience, most recently as Chief Financial Officer at Royalty Pharma from 2005 until her retirement in 2019. During her tenure, she grew the company’s debt facilities from approximately $200 million to $7 billion, oversaw more than $20 billion in total financing, and raised $2.0 billion in equity capital. Prior to Royalty Pharma, she spent 14 years in investment banking, including as Managing Director and senior healthcare analyst at CIBC World Markets, Merrill Lynch and Chase Securities. Ms. Gray currently serves as a director and Chair of the Audit Committee of Maravai LifeSciences, and on the boards of 4D Molecular Therapeutics and AnaptysBio. She previously served as Chair of the Board of Theravance Biopharma until its acquisition by Zymeworks in September 2026. She also serves on the board of directors of Susan G. Komen and the board of trustees of Wesleyan University. Ms. Gray holds a BA with honors from Wesleyan University and an MBA from Columbia University.

“Talawar is entering an important new chapter as it prepares to become a public company, and I look forward to helping build the financial infrastructure to support that transition,” said Ms. Gray. “I’m honored to work alongside this Board and management team as they advance TALA-125 and the Company’s broader pipeline.”

About Talawar Therapeutics

Talawar Therapeutics is a biotechnology company developing potentially best-in-class bispecific antibodies that pair independent disease drivers in a single therapy, targeting pathways that work together for greater, more durable impact. Our lead program, TALA-125, is a novel anti-IL-13 x anti-IL-18 bispecific that combines two clinically validated, largely orthogonal mechanisms designed to shatter the current limitations of existing treatments — with broad applicability across first-line patients and those who have failed previous therapies. Talawar is the first company formed to develop and commercialize assets discovered by Khanda Therapeutics, L.P. For more information, visit www.talawartx.com.

Media Contact

Marites Coulter
Deerfield Group
marites.coulter@deerfieldgroup.com